iRhythm (NASDAQ: IRTC) is a publicly traded Health & Biometric Sensing company founded in 2006 and based in San Francisco, United States.
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Oct 20, 2016 | IPO | — | — | — |
iRhythm reported Q3 2026 revenue of $221.6 million, up 14.9% from $192.9 million in Q3 2025. Gross margin was 74.2%, a 310-basis point increase from the prior-year quarter; the release attributes part of the gross profit increase to a one-time tariff refund benefit of approximately $3.1 million. GAAP net loss widened to $29.9 million ($0.90 per diluted share) from $5.2 million ($0.16) a year earlier, driven by $49.8 million in litigation settlements within operating expenses. Adjusted EBITDA was $51.2 million (adjusted EBITDA margin 23.1%), and adjusted net income was $27.8 million ($0.82 adjusted diluted EPS). Operationally, the company cited volume-led Zio Monitor demand across cardiology, primary care and international channels; the completed October 5, 2026 acquisition of VitalConnect; three published real-world studies; and FDA 510(k) submissions for pediatric use of Zio Monitor. It also closed a $300 million senior secured revolving credit facility on November 3, 2026. Cash, cash equivalents and marketable securities were $560.7 million at September 30, 2026. Full-year 2026 guidance was raised to revenue of $890–$895 million (including about $16 million from VitalConnect) and adjusted EBITDA margin of 15.5%–16.0%.
FY2026 revenue $890–$895M (incl. ~$16M VitalConnect); adjusted EBITDA margin 15.5%–16.0%
iRhythm Technologies publishes the transcript of its Q3 2026 earnings call.

iRhythm posts a wider Q3 loss after a $50M patent-settlement expense.
Analysis piece on whether ECG device makers will license arrhythmia analysis software rather than build it in-house.
The Zio System is iRhythm's flagship ambulatory cardiac monitoring solution, combining an FDA-cleared, CE-marked wire-free, patch-based wearable biosensor with proprietary cloud-based analytics. The Zio patch is worn on the chest for up to 14 days, continuously recording single-lead ECG data while the patient goes about daily life. After wear, the recording is analyzed by iRhythm's deep-learning algorithms and curated by technicians into a report that helps physicians diagnose arrhythmias such as atrial fibrillation. The Zio AT variant adds near-real-time transmission so clinically significant events can be flagged during the wear period.
iRhythm's cloud platform ingests the continuous ECG captured by Zio patches and applies FDA-cleared deep-learning algorithms to detect and classify cardiac arrhythmias across the full multi-day recording. The system combines automated analysis with technician review to produce comprehensive diagnostic reports for cardiologists and primary-care physicians, surfacing burden and patterns that shorter Holter monitors often miss. Having processed millions of patient recordings, the platform forms the recurring, data-driven core of iRhythm's business, turning each disposable wearable sensor into a billable diagnostic service.